Estrogen signalling and the metabolic syndrome: targeting the hepatic estrogen receptor alpha action.

ABSTRACT: An increasing body of evidence now links estrogenic signalling with the metabolic syndrome (MS). Despite the beneficial estrogenic effects in reversing some of the MS symptoms, the underlying mechanisms remain largely undiscovered. We have previously shown that total estrogen receptor alpha (ER?) knockout (KO) mice exhibit hepatic insulin resistance. To determine whether liver-selective ablation of ER? recapitulates metabolic phenotypes of ERKO mice we generated a liver-selective ER?KO mouse model, LERKO. We demonstrate that LERKO mice have efficient reduction of ER? selectively within the liver. However, LERKO and wild type control mice do not differ in body weight, and have a comparable hormone profile as well as insulin and glucose response, even when challenged with a high fat diet. Furthermore, LERKO mice display very minor changes in their hepatic transcript profile. Collectively, our findings indicate that hepatic ER? action may not be the responsible factor for the previously identified hepatic insulin resistance in ER?KO mice.

SUBMITTER: Matic M 

PROVIDER: S-EPMC3581463 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature